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Summary
The ubiquitin proteasome system (UPS) is known to be
responsible for the rapid turnover of many transcription
factors, where half-life is held to be critical for regulation of
transcriptional activity. However, the stability of key
transcriptional regulators of development is often very
poorly characterised. Neurogenin 3 (Ngn3) is a basic helix–
loop–helix transcription factor that plays a central role in
specification and differentiation of endocrine cells of the
pancreas and gut, as well as spermatogonia and regions of the
brain. Here we demonstrate that Ngn3 protein stability is
regulated by the ubiquitin proteasome system and that Ngn3
can be ubiquitylated on lysines, the N-terminus and, highly
unusually, on non-canonical residues including cysteines and
serines/threonines. Rapid turnover of Ngn3 is regulated both
by binding to its heterodimeric partner E protein and by the
presence of cdk inhibitors. We show that protein half-life does
appear to regulate the activity of Ngn3 in vivo, but, unlike
the related transcription factor c-myc, ubiquitylation on
canonical sites is not a requirement for transcriptional
activity of Ngn3. Hence, we characterise an important new
level of Ngn3 post-translational control, which may regulate
its transcriptional activity.
 2012. Published by The Company of Biologists Ltd. This is
an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial Share Alike
License (http://creativecommons.org/licenses/by-nc-sa/3.0).
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Introduction
Development of the early embryo requires dynamic regulation of
key regulatory molecules that drive and co-ordinate developmental
processes. In particular, master regulatory transcription factors are
often subject to stringent controls both at the level of their own
transcription and by post-translational mechanisms. For example,
ubiquitin-mediated proteolysis has been shown to be a requirement
for transcriptional activity of the basic helix–loop–helix (bHLH)
transcription factor c-myc (von der Lehr et al., 2003; Kim et al.,
2003). Members of a related class of bHLH transcription factors
include the proneural Neurogenin (Ngn) transcription factor family,
which controls processes such as neuronal differentiation,
endocrine pancreas formation and regulation of spermatogenesis
(Massari and Murre, 2000; Yoshida et al., 2004).
While regulation of the level of proneural protein transcripts
has been well documented, their post-translational regulation is
much less well understood. However, recent studies have begun
to shed light on several post-translational mechanisms that
control Ngn2, a master regulator of neurogenesis. In particular, it
has been demonstrated that Ngn2 is a very short-lived protein that
is rapidly degraded by the ubiquitin proteasome system (UPS)
(Vosper et al., 2007). This method of regulated protein
degradation requires covalent linkages to the small ubiquitin
(Ub) protein via a cascade of ubiquitin-conjugating and ubiquitin
ligase enzymes: once an appropriate chain of at least 4 Ub
moieties is attached to the substrate protein, it can be targeted for
destruction by the proteasome (Thrower et al., 2000).
Ubiquitylation has classically been described to occur via an
isopeptide linkage to substrate lysines (Hershko and Ciechanover,
1998), while ubiquitylation has also been demonstrated to occur by
direct linkage to the free N-terminus of about a dozen proteins
(Ciechanover and Ben-Saadon, 2004). These so-called canonical
sites of ubiquitylation were originally thought to be the sole sites of
Ub attachment during physiological ubiquitylation. However,
recently it has become clear that non-canonical ubiquitylation can
occur on a small number of proteins via thioester and ester linkage
to substrate cysteines and/or serines and threonines, often using
viral ubiquitin ligase enzymes and sometimes resulting in a change
of substrate sub-cellular localisation (Cadwell and Coscoy,
2005; Carvalho et al., 2007; Williams et al., 2007). We have
demonstrated recently that, highly unusually, Ngn2 can be
ubiquitylated on non-canonical sites by cellular ubiquitin ligases
and that these linkages alone can target Ngn2 for destruction
(Vosper et al., 2009; McDowell et al., 2010). While ubiquitylation
on cysteines can occur in interphase or mitosis of the cell cycle,
cysteine ubiquitylation of Ngn2 is limiting for degradation only in
mitosis (Vosper et al., 2009).
The related proneural transcription factor Neurogenin 3 (Ngn3)
is required for cells to adopt an endocrine rather than an exocrine
cell fate during development of both the pancreas and the gut
(Schwitzgebel et al., 2000; Bertrand et al., 2002; Gu et al., 2002;
Jenny et al., 2002). Tamoxifen-inducible Ngn3, under the control
of the pdx1 promoter, has been used in mice to regulate Ngn3
activity at increasing developmental stages, and these studies
show that, at defined developmental times, Ngn3 can drive
differentiation towards all endocrine pancreatic lineages
(Johansson et al., 2007). Moreover, at the appropriate stage,
high levels of Ngn3 cause cells to exit the cell cycle and promote
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formation of insulin-expressing cells at the expense of exocrine
pancreas (Johansson et al., 2007), indicating that manipulation
of Ngn3 levels and/or activity may be highly beneficial for
differentiation or transdifferentiation of cells to treat deficiencies
of the endocrine pancreas such as diabetes.
Despite its central role in pancreatic development, the post-
translational regulation of Ngn3 has barely been investigated.
Ngn3 is 89% identical at the amino acid level to Ngn2 in the
bHLH region, but only 43% similar outside it. Therefore,
regulation of proteolytic degradation of Ngn3 may differ
significantly from that of Ngn2. With this in mind, we set out
to characterise the regulation of Ngn3 degradation using the
highly tractable biochemical system afforded by the use of
Xenopus egg extracts, identifying similarities and differences in
regulation of ubiquitylation and proteolysis between the two
proteins.
Here, we show that Ngn3 has a very short half-life and is
degraded by ubiquitin-mediated proteolysis. We show that Ngn3
joins the very small number of proteins known to undergo
extensive non-canonical ubiquitylation on cysteine, serine and/or
threonine residues. However, in contrast to Ngn2, this non-
canonical ubiquitylation does not contribute significantly to
Ngn3’s rapid turnover. We show that Ngn3 half-life is extended
by binding to its heterodimeric E protein partner. In addition,
Ngn3 is stabilised by the presence of a Cip/Kip family cyclin-
dependent kinase inhibitor, indicating cell cycle regulation of
proteolytic turnover. It has previously been proposed that
ubiquitin-mediated proteolysis may be a requirement for
activity of some transcription factors (Kim et al., 2003; von der
Lehr et al., 2003; Collins and Tansey, 2006). Finally, we show
that canonical ubiquitylation is not absolutely required for
Ngn3’s ability to drive transcription, but it may play a role in
regulating the level of Ngn3 transcriptional activity in vivo.
Results
Ngn3 is an unstable protein degraded by the UPS
Cytoplasmic extract prepared from activated Xenopus eggs by
centrifugation contain all the ubiquitin–proteasome system (UPS)
components required to target Ngn2 for ubiquitylation and
degradation, and provide a convenient system to investigate sites
of ubiquitylation of targeted proteins. To determine whether
Ngn3 was degraded by the UPS in these extracts, we prepared
35S-methionine-labeled in vitro translated Ngn3 protein in rabbit
reticulocyte lysate (IVT Ngn3). IVT Ngn3 was incubated in
interphase egg extract with and without the synthetic peptide
proteasome inhibitor Mg132, at a dose previously shown to
stabilise Ngn2 in egg extract (Vosper et al., 2007), and samples
removed at increasing time-points for analysis by SDS
Polyacrylamide Gel Electrophoresis (SDS PAGE).
Ngn3 is unstable in Xenopus egg extracts, with a half-life of
14.461.7 minutes in the absence of Mg132 (Fig. 1A), even shorter
than the half-life of Ngn2 (approximately 22 minutes (Vosper et al.,
2007)). Ngn3 is significantly stabilised by Mg132, averaging a half-
life of 66.064.5 minutes (Fig. 1). Failure of Mg132 to completely
stabilise Ngn3 may reflect only partial inhibition of the proteasome,
or else could indicate that Ngn3 can also be degraded by non-
proteasomal pathways. We also see retardation of Ngn3 protein
after incubation in egg extract (compare t50 and t515 time-
points). Ngn2 is highly phosphorylated in egg extracts (Ali et al.,
2011; Hindley et al., 2012) and it is likely that Ngn3 is similarly
modified. Xenopus interphase egg extracts can be driven into a
stable mitotic state by addition of CycBD90, a non-degradable form
of cyclin B (Glotzer et al., 1991), and cell cycle stage of the extract
significantly alters half-life in a number of proteins including Ngn2
(Vosper et al., 2007). We determined the relative half-life of Ngn3
in mitotic extract using the method described above. Unlike Ngn2,
whose half-life is significantly shortened in mitosis, the stability of
Ngn3 in mitotic extract is similar to that in interphase, with a half-
life of 15.061.4 minutes in the absence of Mg132 and
70.062.0 minutes in the presence of Mg132 (Fig. 1).
Identification of sites of ubiquitylation in Ngn3
The vast majority of ubiquitylated cellular proteins undergo
modification of lysine residues via an isopeptide linkage to Ub. A
much smaller number of proteins have been shown to be
Fig. 1. Ngn3 is degraded by ubiquitin-mediated proteolysis in interphase
and mitosis. Degradation assays were performed in interphase (A) and mitotic
(B) Xenopus egg extract using 35S-IVT Ngn3 in either the presence or absence
of 100 mM Mg132 proteasome inhibitor. Samples were run on SDS-PAGE gels,
analysed by autoradiography (A,B) and quantified by phosphorimaging
(C). Degradation half-lives were calculated using first-order rate kinetics
(D). In C, the solid line shows degradation in interphase extracts, and the dotted
line shows degradation in mitotic extracts.
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ubiquitylated directly onto the N-terminus, and only a handful
have been demonstrated to undergo ubiquitylation on non-
canonical sites including cysteine, serine and/or threonine
(Ciechanover and Ben-Saadon, 2004; Carvalho et al., 2007;
Cadwell and Coscoy, 2005; Williams et al., 2007). Perhaps
uniquely, Ngn2 has been shown to use all three of these modes of
ubiquitylation to direct protein degradation (McDowell et al.,
2010). Therefore, in this study, we set out to determine the sites
of ubiquitylation that can target Ngn3 for UPS-mediated
degradation in interphase egg extracts. To this end, mutant
forms of Ngn3 were created to remove putative sites of canonical
and non-canonical ubiquitylation.
To block ubiquitylation on lysine residues we generated a
mutant form of Ngn3 in which all 7 lysines are mutated to
arginine (Ngn3KO). Co-translational N-terminal acetylation is
incompatible with N-terminal ubiquitylation (Kuo et al., 2004).
The N-terminal acetylation prediction tool TermiNator (available
from the CNRS) predicts that the likelihood for co-translational
acetylation of wild-type Ngn3 on its N-terminus is 22%, so there
is a good likelihood that this site would be available for
ubiquitylation. To prevent this, we mutated the first 5 amino
acids to a sequence that is predicted to be N-terminally acetylated
with an 83% likelihood of producing acetylated Ngn3 (AcNgn3).
A similar mutational strategy was used to block N-terminal
ubiquitylation on Ngn2 (Vosper et al., 2009). We then combined
both types of mutation to generate AcNgn3KO, which contains
no canonical sites of ubiquitylation. We then tested the ability of
these mutated proteins to be ubiquitylated.
We have previously shown that wild-type Ngn2 is ubiquitylated
on cysteines even when lysines are present (Vosper et al., 2009). In
the present study, we set out to determine whether wild-type Ngn3
is also ubiquitylated on non-canonical residues and, if so, whether
this modification occurs in the native protein or only in the absence
of lysines. To this end, His-tagged ubiquitin precipitation assays
were performed in interphase egg extract on wild-type Ngn3 and
mutants thereof, as described above. IVT Ngn3 protein was
incubated in interphase egg extract along with His-tagged ubiquitin
or untagged ubiquitin, as a negative control, in the presence of the
proteasome inhibitor Mg132. After ubiquitylation was allowed to
occur, ubiquitylated proteins were isolated by binding to Ni-NTA
agarose beads, and washed in buffer containing 8M urea to remove
non-covalently bound proteins. Ubiquitylated proteins were then
eluted into SDS PAGE loading buffer under either non-reducing
conditions (pH 6.8) designed to retain weaker thioester/ester Ub
linkages or high pH, highly reducing conditions (10% (v/v) b-
mercaptoethanol, pH 10.5), which should both reduce thioester
bonds and hydrolyse ester linkages efficiently. All samples were
heated at 95 C˚ for 5 minutes prior to separation by SDS PAGE.
Ngn3 becomes extensively ubiquitylated after incubation in
interphase extract, resulting in a ladder of poly-Ub forms of the
protein with retarded migration on SDS PAGE, the most
prominent rapidly migrating form running higher than the
approx. 35 KDa of the unconjugated protein (Fig. 2A,B). More
highly conjugated forms run as a ladder rising up the gel with the
most poly-ubiquitylated forms running together above the 70 kDa
molecular weight marker. In contrast, no Ngn3 is pulled down
using untagged Ub in this assay (data not shown), demonstrating
that all protein detected is a result of covalent attachment to Ub.
AcNgn3 shows a similar pattern of ubiquitylation to that of the
wild-type protein (Fig. 2), with a poly-Ub ladder still rising to the
top of the gel. However, the lysineless variants Ngn3KO and
AcNgn3KO show both a ladder of poly-Ub forms and a prominent
band running at approximately 35 kDa, the size at which native
unconjugated Ngn3 migrates on SDS PAGE (Fig. 2A,C, arrow).
Highly reducing conditions have little effect on Ub ladders of
Ngn3 and AcNgn3 (Fig. 2C compared to Fig. 2B) demonstrating
covalent ubiquitylation. In contrast, ubiquitylated forms of
lysineless variants Ngn3KO and AcNgn3KO are essentially lost
in reducing conditions (see loss of retarded bands between 35KDa
and the top of the gel in these samples), although the prominent
band of unconjugated Ngn3 (Fig. 2C, arrow) remains. These
results are consistent with the predominant Ub linkages in the
wild-type protein occurring via stable isopeptide bonds to lysines,
whereas Ub on lysineless variants occurs via labile ester and
thioester linkages to non-canonical Ub acceptor sites, disrupted by
high pH and reducing conditions. However, we noted that
ubiquitylated Ngn3 and AcNgn3 do release a detectable band of
unconjugated protein running at approx. 35 kDa, particularly after
reducing treatment (Fig. 2C, arrow), indicating that a subset of
even these proteins that retain lysines are ubiquitylated via labile
linkages. These labile linkages are likely to include cysteine
residues (Vosper et al., 2007). To test this, we generated further
Ngn3 mutants in which cysteines were mutated to alanines either
in a wild-type background to generate Ngn3CO or in the presence
of additional mutations of canonical ubiquitylation sites to
generate Ngn3KOCO and AcNgn3KOCO. We then tested the
ability of each mutant to be ubiquitylated.
The patterns of ubiquitylated forms of Ngn3CO and
Ac3Ngn3CO were indistinguishable from those of Ngn3 and
Fig. 2. Ubiquitylation of Ngn3 and mutants on canonical and non-
canonical sites. Ubiquitylation assays were performed in interphase Xenopus
egg extract using 35S-labeled IVT Ngn3 and mutants as labelled, in the presence
of His-tagged ubiquitin (B,C). IVT protein levels were normalised, as
demonstrated by the levels of starting material shown in A. Proteins were eluted
from NTA-agarose beads using either non-reducing conditions (pH 6.8) (B) or
highly reducing conditions (pH 10, 10% (v/v) b-mercaptoethanol) (C).
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AcNgn3 in either non-reducing or reducing conditions (Fig. 2).
Perhaps more surprisingly, there is also no difference in the
pattern of ubiquitylation of Ngn3KO compared to Ngn3KOCO or
of AcNgn3KO compared to AcNgn3KOCO; all these samples
show poly-ubiquitylated forms in non-reducing conditions
releasing unconjugated Ngn3 protein (arrow) under reducing
conditions. These results indicate again that non-canonical
ubiquitylation can occur on Ngn3, but that these Ub events can
occur readily on serines/threonines, regardless of the presence or
absence of cysteines.
Thus, non-canonical ubiquitylation of Ngn3 occurs extensively
in the absence of lysines, but less prominently when lysines are
available. To what extent do canonical and non-canonical
ubiquitylation at distinct types of acceptor residues contribute
to the rapid degradation of Ngn3? To test this we undertook
degradation assays of Ngn3 and of cysteineless Ngn3 derivatives,
with or without mutation of canonical ubiquitylation sites, first in
interphase egg extract.
In interphase egg extract, mutation of lysines approximately
doubled Ngn3 protein half-life (Ngn3 14.861.5 minutes,
Ngn3KO 32.464.2 minutes) (Fig. 3A–C). Blocking N-terminal
ubiquitylation alone had only a very small effect on half-life
(AcNgn3 18.262.5 minutes), indicating that the N-terminus is
not readily used as a site of ubiquitylation to target for destruction
in the otherwise native protein. However, we saw that the half-
life of AcNgn3KO (48.768.9 minutes) was significantly longer
than that of Ngn3KO (32.464.2 minutes), indicating that N-
terminal ubiquitylation is able to direct Ngn3KO degradation
when lysines are no longer available for ubiquitylation.
Nevertheless, AcNgn3KO, which cannot be ubiquitylated on
canonical ubiquitylation sites, is still unstable in interphase (and
less stable than Ngn3 incubated in the presence of Mg132)
(Fig. 1), indicating that non-canonical ubiquitylation can target
Ngn3 for degradation. To test the contribution of ubiquitylation
on cysteine residues to the degradation of Ngn3, we tested the
half-life of various mutants of Ngn3 in which all 3 cysteines had
been mutated to alanines (Ngn3CO mutants).
Ngn3CO was found to have a similar half-life to wild-type Ngn3
(Ngn3CO 18.763.1 minutes, Ngn3 14.861.5 minutes). Likewise,
AcNgn3CO (22.263.8 minutes) has a similar half-life to AcNgn3
(18.262.5 minutes). We also saw that, even when lysines of
Ngn3 have been mutated, further mutation of cysteines has little
effect on half-life. Ngn3KOCO (half-life 38.067.9 minutes) and
AcNgn3KOCO (half-life 49.6613.8 minutes) are not significantly
stabilised in comparison with their counterparts with cysteines intact
(Ngn3KO 32.464.2 minutes, AcNgn3KO 48.768.9 minutes).
Thus, ubiquitylation on cysteines of Ngn3 appears not to
contribute significantly to its degradation in interphase. Moreover,
when the lysines are mutated and the N-terminus is blocked, it is
clear that potential ubiquitylation on cysteines alone is not sufficient
to bring about efficient degradation of Ngn3.
Cysteine ubiquitylation plays a more prominent role in driving
degradation of Ngn2 in mitosis as compared to interphase (Vosper et
al., 2009). To determine whether non-canonical ubiquitylation of
Ngn3 was contributing to rapid protein turnover in mitosis, we also
assayed the half-lives of lysine and cysteine mutants of Ngn3 in
mitotic egg extract (Fig. 3D–F). As in interphase, ubiquitylation on
the N-terminus was not seen to be a significant contributor to
ubiquitin-mediated degradation (Ngn3 10.661.1 minutes, AcNgn3
12.061.1 minutes), except in the absence of internal lysines
(Ngn3KO 29.362.8 minutes, AcNgn3KO 38.063.3 minutes),
when it appears that N-terminal ubiquitylation can target Ngn3KO
for degradation. The mutation of cysteines to alanines does not
result in significant stabilisation of the otherwise native Ngn3
protein in mitotic extract (Ngn3 10.661.1 minutes, Ngn3CO
11.560.2 minutes). These half-life data suggest that the majority
of ubiquitin-mediated degradation of Ngn3 in mitosis, as in
interphase, can be accounted for by ubiquitylation at internal lysines.
Thus, in contrast to Ngn2, which was seen to require cysteines
for its rapid rate of degradation in mitosis (Vosper et al., 2009),
ubiquitylation of cysteines appears to play no role in the rapid
turnover of Ngn3 protein when lysines are available for
ubiquitylation. However, in the absence of viable canonical
ubiquitylation sites, the half-life data presented in Fig. 3F suggest
that ubiquitylation on internal cysteines is capable of targeting
Ngn3 for degradation in mitosis. To illustrate this, in the absence
of internal lysines, Ngn3KO half-life is 29.362.8 minutes, while
the further mutation of cysteines to alanines results in an
increased half-life for Ngn3KOCO of 50.360.5 minutes.
To confirm that the degradation we are seeing in interphase and
mitosis is due to the proteasome, we compared degradation of
Ngn3, AcNgn3, Ngn3KO and AcNgn3KO in the presence and
absence of Mg132 (Fig. 4). In each case, the protein appears
stabilised in the presence of Mg132 and, as expected, stabilisation
is more dramatic for the Ngn3 constructs containing lysines that
have the fastest degradation rate.
Taken together, these results demonstrate that ubiquitylation
and proteasomal degradation can occur via both canonical and
non-canonical cysteine sites in Ngn3, even in the wild-type
protein, but only canonical sites of ubiquitylation, primarily
lysines, have a significant effect on Ngn3 half-life. This is in
contrast to Ngn2, which requires ubiquitylation of both canonical
and non-canonical cysteine sites for rapid turnover of the wild-
type protein. Having established both similarities and differences
in regulation of sites of ubiquitylation and their effect on
degradation between Ngn2 and Ngn3 as described above, we
went on to investigate further potential mechanisms of control of
Ngn3 proteolytic degradation.
The stability of proneural bHLH transcription factors such as
Ngn2 and MASH1 has been shown to be additionally regulated
by association with their heterodimerisation E protein partners,
E12 or E47 (Vosper et al., 2007). We therefore investigated
whether Ngn3 protein is stabilised by the addition of E12. We
mixed IVT Ngn3 and E12 in interphase egg extracts and
investigated Ngn3 stability in our degradation assay. Binding to
E12 resulted in an approximately 4-fold increase in Ngn3 half-
life (Fig. 5A,C).
Cyclin-dependent kinase inhibitors (cdkis) have also been
shown to be required for Ngn2 function, independent of their
ability to inhibit the cell cycle and overall cdk kinase activity. In
vivo, cdkis promote Ngn2 protein accumulation, and may act by
inhibiting ubiquitin-mediated proteolysis (Vernon et al., 2003;
Nguyen et al., 2006). We investigated whether the Xenopus cdki,
Xic1, which shows homology to the mammalian cdkis p21Cip1,
p27Kip1 and p57Kip2, was able to stabilise Ngn3 protein directly
in egg extract. Addition of recombinant Xic1 protein to egg
extract resulted in a 2.5-fold increase in the half-life of IVT Ngn3
(Fig. 5B,C).
It has been suggested that ubiquitylation is important for
activity of some transcription factors, where their rapid
proteolytic turnover may be a prerequisite for promoter activity
(Kim et al., 2003; von der Lehr et al., 2003; Collins and Tansey,
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Fig. 3. Identification of Ngn3 ubiquitylation sites involved in degradation. Degradation assays were performed in interphase (A,B,C) and mitotic
(D,E,F) Xenopus egg extract using 35S-IVT Ngn3 and mutants (including N-terminal acetylation (Ac), lysine to arginine (KO), and cysteine to alanines (CO)
mutations). Samples were run on SDS-PAGE gels, analysed by autoradiography (A,D) and quantified by phosphorimaging (B,E). Degradation half-lives were
calculated using first-order rate kinetics (C,F).
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2006). Conversely, one might hypothesise that increasing the half-
life of this highly unstable protein by inhibiting UPS-mediated
turnover might enhance Ngn3’s transcriptional activity. We
investigated whether ubiquitylation of Ngn3 on canonical sites,
the mode of Ngn3 ubiquitylation that regulates its stability as
demonstrated above, was absolutely required for Ngn3 activity
in vivo in developing Xenopus embryos. DNA binding is a
prerequisite for transcriptional activation, so first we investigated
the ability of AcNgn3KO to bind to E box DNA by electrophoretic
mobility shift assay (EMSA) (Fig. 6).
IVT Ngn3 and AcNgn3KO at two different concentrations
were tested for E box DNA binding ability by EMSA. Ngn3
binds strongly to E box DNA probe dependent on the presence of
E protein, but binding of AcNgn3KO appears somewhat less
efficient (Fig. 6A). This likely reflects an intrinsic difference in
the ability of the mutated AcNgn3KO protein to bind to DNA,
rather than ubiquitylation or other potential modification of
lysines, as this semi-purified system containing only IVT protein
and radiolabelled DNA probe. To recapitulate the environment of
the Xenopus egg and embryo, where ubiquitylation of lysines and
the N-terminus occurs, we then conducted a similar EMSA
analysis in the presence of interphase egg extract, which was
permissive for ubiquitylation but where degradation had
been prevented by addition of Mg132. AcNgn3KO showed
substantially weaker binding to DNA than Ngn3, indicating that
lysines play a greater role in contributing to stable DNA
association in the presence of egg extract when these residues
could be modified (Fig. 6B). Thus, in Xenopus cytoplasm
AcNgn3KO has a considerably longer half-life than Ngn3
(Fig. 1), but has a significantly lower affinity for E-box-
containing DNA (Fig. 6). If both strong DNA binding and
ubiquitylation are required for transcriptional activity, one might
predict that AcNgn3KO would show a significantly reduced
capacity to drive cellular differentiation. However, conversely, an
increased Ngn3 half-life could promote the ability of AcNgn3KO
Fig. 4. Forms of Ngn3 lacking lysines are stabilised by
Mg132. Degradation assays at a fixed point of 90 minutes
were performed in interphase (A) and mitotic (B) Xenopus
egg extract using 35S-IVT Ngn3 and mutants thereof, as
labelled, in either the presence or absence of 100 mM
Mg132 proteasome inhibitor. Samples were run on SDS-
PAGE gels, analysed by autoradiography (A,B).
Fig. 5. Ngn3 is stabilised by E12 and Xic1 in interphase Xenopus egg
extract. Degradation assays were performed in the presence of either (A) IVT
E12 (at a 1:1 volume ratio to Ngn3) or IVT mix alone, or (B) 15 mM Xic1-MBP
or 15 mM MBP as a control. Samples were run on SDS-PAGE gels, analysed by
autoradiography (A,B) and quantified by phosphorimaging. Degradation half-
lives were calculated using first-order rate kinetics (C).
Fig. 6. AcNgn3KO binds DNA less tightly than Ngn3. Ngn3, AcNgn3KO,
Ngn2 and AcNgn2KO binding to E box-containing probe, with or without
added E protein as indicated, were assayed by EMSA either in buffer alone
(A) or in the presence of interphase egg extract (B), triangle representing two
different amounts of each IVT (see Materials and Methods).
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to drive transcription by increasing promoter occupancy time and
this may compensate for weaker DNA binding. To test this, we
compared the ability of Ngn3 and AcNgn3KO to drive a
downstream transcriptional program in vivo, in Xenopus
embryos.
Ngn3 upregulates a large number of direct downstream targets
to control differentiation of endocrine cells of the gut and
pancreas, among other tissues (Gradwohl et al., 2000; Juhl et al.,
2008). These differentiation pathways have several key
downstream effectors in common with those required to induce
neurogenesis by Ngn2, such as NeuroD and Delta. Indeed,
experimentally, Ngn3 overexpression in early Xenopus embryos
results in upregulation of NeuroD and Delta, converting
epidermis to a neural fate (Huang et al., 2000) (Fig. 7; data not
shown), providing a convenient assay for Ngn3 transcriptional
activity in vivo. Using this assay, we compared the abilities of
Ngn3 and AcNgn3KO to induce ectopic neurogenesis in Xenopus
after mRNA micro-injection, using in situ hybridisation for
neural b tubulin to detect ectopic differentiated neurons.
Ngn3 induced formation of ectopic primary neurons in a dose-
dependent manner, where 25 pg micro-injected mRNA produced
substantially more extensive neurogenesis than 5 pg. Surprisingly,
5 pg AcNgn3KO showed very similar activity to 5 pg Ngn3, and at
25 pg, AcNgn3KO was only marginally less active than the wild-
type protein. This contrasts with the effect of a lysineless mutant of
Ngn2 (Vosper et al., 2009); AcNgn2KO showed very low levels of
ectopic neurogenesis compared to its wild-type counterpart, Ngn2.
From these results, it is clear that rapid ubiquitin-mediated
proteolysis is not a prerequisite for Ngn3 transcriptional activity,
unlike the related bHLH protein c-myc (Kim et al., 2003; von der
Lehr et al., 2003; Collins and Tansey, 2006). Moreover, these
results indicate that the increased half-life of AcNgn3KO may
compensate for reduced DNA binding, allowing the protein to
retain considerable activity in vivo.
Discussion
Xenopus egg extracts provide an ideal system for detailed
biochemical analysis of mechanisms regulating Ngn3
degradation, as it contains stockpiles of E1, E2 and E3 enzymes
and proteasomal components required for its ubiquitin-mediated
destruction. Xenopus also provides a versatile system for
measuring Ngn3 activity; while found in the hypothalamus and
hippocampus (Sommer et al., 1996; Simon-Areces et al., 2010),
Ngn3 is not endogenously expressed in most tissues of the brain
during development. However, when exogenously expressed,
Ngn3 can activate neuronal differentiation in Xenopus ectoderm
primed for this fate in a dose-dependent manner by activating
NeuroD (Huang et al., 2000) (data not shown), on a par with
neuronal activation by Ngn2. Hence, overexpression by mRNA
microinjection provides a convenient system to semi-
quantitatively monitor Ngn3’s transcriptional activity. Here we
have used both Xenopus egg extracts and expression in developing
Fig. 7. Ngn3 and AcNgn3KO show similar activity in
vivo. 1 cell of a 2 cell-stage Xenopus embryo was injected
with mRNA encoding GFP (as a control, A), Ngn3
(B,C), AcNgn3KO (D,E), Ngn2 (F) or AcNgn2KO (G) in
the amounts as indicated, along with bgal mRNA as a
lineage tracer. Expression of neural b tubulin at stage 15
was assayed by in situ hybridisation. A semi-quantitative
scoring method for neural b tubulin expression was devised
(H), where 0 5 no ectopic neurogenesis, 1 5 low levels of
ectopic neurogenesis, 2 5 moderate ectopic neurogenesis
and 3 5 extensive ectopic neurogenesis (number of
embryos scored per condition: between 49 and 69).
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Xenopus embryos to undertake a detailed study determining modes
of Ngn3 ubiquitylation and their relationship with rates of
degradation. We have also investigated the role of co-factors in
control of Ngn3 protein half-life and the relationship between
ubiquitylation and Ngn3 transcriptional activity.
The results presented here suggest that, in both interphase and
mitosis, the N-terminus of Ngn3 is a viable site of ubiquitylation
in the absence of lysines, but that it is not significantly involved
in ubiquitin-mediated degradation of wild-type Ngn3. Our results
also show that Ngn3 can join the very small number of identified
proteins that can undergo non-canonical ubiquitylation via labile
thioester or ester bonds between ubiquitin and residues such as
cysteines, serines, or threonines.
Although Ngn2 and Ngn3 share important downstream targets,
and although they are both regulated by the UPS, our results reveal
major differences between the ubiquitin-mediated regulation of
Ngn2 and Ngn3. We previously saw that wild-type Ngn2 was
targeted for degradation in mitosis by ubiquitylation not only on
internal lysines and the N-terminus, but also on internal cysteines
and potentially also serines and/or threonines (Vosper et al., 2009;
McDowell et al., 2010). Unlike Ngn2, we see that Ngn3 is targeted
for proteasome-mediated degradation overwhelmingly by
ubiquitylation at internal lysines (Fig. 3) in interphase and
mitosis. One reason for this difference between Ngn2 and Ngn3
may be that Ngn3 has only 3 cysteines, compared to 7 cysteines in
Ngn2. These experiments do, however, show evidence of
ubiquitylation on sites other than lysines, cysteines, and the N-
terminus (most likely on serines/threonines) of Ngn3 leading to
degradation, as the mutation of lysines, cysteines, and N-terminus
(resulting in AcNgn3KOCO) is less stabilising than the addition of
proteasome inhibitor Mg132 (Figs 1, 2).
These data also point to a significant promiscuity in the
ubiquitylation machinery that results in Ub moieties being passed
to any available acceptor in the absence of available lysines. Sites
of ubiquitylation need to be near unstructured protein regions to
target for proteasome-mediated unfolding and degradation
(Prakash et al., 2004). It seems likely that Ngn3, like its relative
Ngn1 (Aguado-Llera et al., 2010), may be largely unstructured.
This could potentially give considerable flexibility in the use of
different sites of ubiquitylation to target for destruction, and
provide few intrinsic structural constraints for specifying precise
sites of ubiquitylation.
Boosting transcript levels of Ngn3, as a central regulator of
endocrine pancreas formation, has been extensively investigated
as a means of potentiating islet formation in cell replacement
therapies for diabetes (for a review, see Miyatsuka et al., 2008).
However, enhancing protein activity post-translationally may be
more amenable to practical manipulation by extrinsic factors than
introduction or overexpression of the Ngn3 gene, when designing
stem cell differentiation protocols. A full understanding of the
relationship between Ngn3 protein stability and activity will be
essential for this. We see that Ngn3 is ubiquitylated on both
canonical and non-canonical ubiquitin acceptor sites. However,
our results indicate that non-canonical ubiquitylation plays a
minimal role in rapid degradation of the native Ngn3 protein. A
mutant Ngn3 protein, in which all lysines have been mutated,
shows much reduced DNA binding, yet retains substantial
activity in vivo, indicating that increased protein half-life can
promote transcriptional activity of Ngn3 even when its DNA
binding ability is compromised. In addition, Ngn3 half-life can be
increased by cdki expression.
Taken together, our results could have significant implications
for control of Ngn3 availability and activity for in vitro
manipulation of stem cell fate; our results indicate that
increasing half-life of Ngn3 in cells might be achieved either by
increasing cdki expression, which would have the additional effect
of slowing or stopping cell cycling, and/or by identification and
manipulation of the E3 ligase(s) that target Ngn3 for
ubiquitylation.
The findings presented here, along with other recent reports of
non-canonical ubiquitylation, indicate that ubiquitin-mediated
protein turnover is far more complex, and the ubiquitylation
machinery far more flexible, than initially recognised. Although
Ngn2 and Ngn3 are members of the same family and can activate
many of the same downstream targets, regulation of their
proteolysis differs significantly, demonstrating the need to take
care in extrapolating findings from one protein family member to
another.
Materials and Methods
Plasmid constructs
Mouse Ngn3 was cloned into pCS2+. AcNgn3 was created by PCR as previously
described (Vosper et al., 2009). Ngn3KO and AcNgn3KO were synthesised
commercially (GeneCust) and cloned into pCS2+. From these constructs, CO
mutants Ngn3CO, AcNgn3CO, Ngn3KOCO, and AcNgn3KOCO were created by
site-directed mutagenesis, using the QuikChangeH multisite-directed mutagenesis
kit (Stratagene).
Degradation assays
Activated interphase and mitotic Xenopus egg extracts were prepared and
supplemented with ubiquitin as previously described (Vosper et al., 2007;
Vosper et al., 2009). 35S-labeled IVT Ngn3 was generated in rabbit reticulocyte
lysate (Promega) containing 35S-methionine (Perkin Elmer). 35S-IVT Ngn3 (or
mutant derivatives thereof) was added to egg extract (18% (v/v) 35S-IVT Ngn3)
and incubated at 20 C˚. At indicated time-points, aliquots were removed and mixed
with Laemmli sample buffer supplemented with 100 mM b-mercaptoethanol.
Samples were heated at 95 C˚ for 5 minutes and run out on SDS-PAGE gels (15%
Tris-glycine). Gels were analysed visually by autoradiography and quantitatively
by phosphorimaging (Fujifilm). Degradation half-lives were calculated using first-
order rate kinetics, using a natural log (ln) scale (Vosper et al., 2007). Three
repeats of each degradation assay were performed and analysed.
Ubiquitylation assays
His-ubiquitin precipitation assays were performed, under both non-reducing and
highly reducing conditions, as previously described with minor alterations (Vosper
et al., 2009). Interphase Xenopus egg extract was supplemented with 20 mM
Mg132 (BioMol) and 2.5 mg/ml of either His-ubiquitin or untagged ubiquitin
(both Sigma). IVT Ngn3 (or mutant) (20% (v/v)) was added to this supplemented
extract and incubated at 20 C˚ for 90 minutes. Each reaction was then diluted 10-
fold in His buffer (8 M urea, 600 mM NaCl, 20 mM imidazole, 100 mM Tris
pH 7.4, 10% ethanol, 1% (v/v) IgePal), supplemented with 15 ml Ni-NTA agarose
(Qiagen), and incubated at 20 C˚ for 90 minutes (12 rpm). Following this
incubation, beads were washed 3 times with His buffer. His-conjugated proteins
were eluted from nickel beads by the addition of 15 ml 26 Laemmli buffer and
heating at 95 C˚ for 5 minutes. For non-reducing conditions, the Laemmli buffer
was prepared at pH 6.8 with no b-mercaptoethanol. For highly reducing
conditions, the Laemmli buffer was prepared at pH 10.0 with 10% (v/v) b-
mercaptoethanol. Eluted proteins were separated on SDS-PAGE gels (15% Tris-
glycine), which were analysed by autoradiography.
Electrophoretic mobility shift assays (EMSAs)
EMSAs were undertaken as previously described (Ali et al., 2011). Either IVT E12
(25% (v/v)) and wild-type or mutant Ngn3 (as indicated) (12.5% or 25% (v/v))
were incubated in activated interphase Xenopus laevis egg extract (50% (v/v))
supplemented with 20 mM Mg132 for 20 minutes at RT (Fig. 5B) before dilution
to 40% (v/v) in binding buffer. Alternatively, IVT E12 (10% (v/v)) and wild-type
or mutant Ngn3 (as indicated) (5% or 10% (v/v)) (Fig. 6A) were immediately
incubated in binding buffer. Incubations in binding buffer took place at RT for
20 minutes with synthetic non-specific competitor poly(dI–dC) and 32P-labeled
probe consisting of the E1 E box domain of the NeuroD promoter. Samples were
then separated on a non-denaturing 5% Bis–Tris gel, which was dried and analyzed
by autoradiography.
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Xenopus laevis extracts and embryos
Acquisition of Xenopus laevis eggs and embryos, preparation and injection of
synthetic mRNA, staging of embryos, in situ hybridisation and egg extracts
preparation have been described previously (Vernon et al., 2003; Vosper et al.,
2007; Vosper et al., 2009).
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